[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

Official title

Exploratory, Prospective, Single-Arm, Open-labeled Study of [Ga68]MTP220 PET for First-in-Human Biodistribution and Efficacy in Patients With Pancreatic Cancer and Head and Neck Cancers

Overview

The goal of this research study is to develop a diagnostic tool to help with detection and diagnosis of head and neck cancer (HNC) and pancreatic cancer (PaC). This tool is called a "targeted PET tracer", or more specifically a drug named "\[Ga-68\]MTP220". The U.S. Food and Drug Administration (FDA) has not yet approved this drug, so researchers are conducting this research study to see if \[Ga-68\]MTP220 is safe and effective at diagnosing pancreatic cancer and head and neck cancer. FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application. Participants will receive a single injection of \[Ga-68\]MTP220 followed by PET/CT imaging at three points after they received the drug. These study procedures will take about 2.5 hours. Participants will also receive a follow-up phone call the day after receiving the drug to talk about any side effects they experienced.

Detailed description

For HNC, the overall 5-year survival rate of HNSCCs remains ∼40-50%. PaCa is the 3rd leading cause of cancer mortality in the US with its incidence expected to double by 2030. The poor survival of HNC and PaCa patients is partly due to the delayed diagnosis. Thus, early detection and diagnosis is pivotal to improve the survival. Currently, there is still an unmet clinical need for novel diagnostic technologies for early accurate detection and diagnosis of HNC and PaCa. In this exploratory first in human phase 0 trial, researchers are testing the use of a \[Ga-68\]MTP220 as a targeted PET tracer to explore the biodistribution, dosimetry, efficacy and safety in pancreatic and head and neck cancer patients.

Interventions

• Drug [Ga-68]MTP220 PET/CT Scan
  Participants will undergo PET/CT imaging after they have received an injection of the targeted PET tracer drug, \[Ga-68\]MTP220.

Primary outcome measures

• Biodistribution of [Ga-68]MTP220 in patients with pancreatic cancer and head and neck cancers, as measured by standardized uptake value (SUV) mean and maximum [Time frame: Time it takes to do imaging study procedures, about 2.5 hours]
• Radiation dosimetry of [Ga-68]MTP220, as measured by dosimetry calculations performed using site software [Time frame: Time it takes to do imaging study procedures, about 2.5 hours]

Secondary outcome measures (8)

• Safety of [Ga-68]MTP220, as measured by number of participants who experience adverse events (AEs) [Time frame: Participants will be asked to report AEs via telephone follow-up no more than 1 day after they undergo study imaging]
• Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in blood pressure [Time frame: Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes]
• Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in heart rate [Time frame: Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes]
• Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in respiratory rate [Time frame: Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes]
• Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in blood oxygen saturation [Time frame: Baseline (10 minutes before dose) and at the following points after they received the dose: 10, 50, 90, 140 minutes]
• Safety of [Ga-68]MTP220, as measured by number of participants who experience a significant change in electrocardiogram (ECG) [Time frame: Baseline (10 minutes before dose) and at the following points after the start of they received the dose: 10 and 140 minutes]
• Efficacy of [Ga-68]MTP220 PET/CT imaging in detecting PaCa or HNC, as measured by comparison of tumor vs normal tissue uptake of [Ga-68]MTP220, compared to conventional imaging (when available) [Time frame: Time it takes to do imaging study procedures, about 2.5 hours]
• Potential of [Ga-68]MTP220 PET/CT for assessing tumor response to immunotherapy in PaCa and HNC, as measured by radiotracer uptake in tumors as compared to background activity, compared to conventional imaging (when available) [Time frame: Time it takes to do imaging study procedures, about 2.5 hours]

Eligibility criteria

Inclusion criteria

• Participants older than 18 years old
• Prior biopsy showing pancreatic or head and neck malignancy
• Participants have been newly diagnosed and not yet received definitive therapy (including surgery, radiation therapy, or systemic therapy).
• Able and willing to provide written informed consent before any protocol-specific procedures are undertaken
• Participants willing and able to undergo a PET/CT

Exclusion criteria

• Participants who do not meet the above mentioned inclusion criteria
• Participants with severe hepatic and renal dysfunction (Total bilirubin > 3 mg/dL, Albumin < 2.8 g/dL, INR > 2.3 (or prolonged PT), presence of ascites or hepatic encephalopathy (Grade III-IV) End-Stage Renal Disease (ESRD) or eGFR < 30 mL/min/1.73m², Serum creatinine > 4 mg/dL or rapidly rising, Need for dialysis (hemodialysis or peritoneal dialysis), uremic symptoms)
• Participants < 18 years old
• Participants who refuse to give or are unable to sign the informed consent
• Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks
• Participants unable to withstand or undergo PET/CT
• Pregnant or breast feeding women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Diagnostic

Study locations

United States · 1 center

• University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland

Identifiers

NCT: NCT07026981 · CASE1Y25

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗